Novo, GSK and Amgen-backed NK oncology therapy developer Nkarta Therapeutics has set a range that will net it between $140m and $160m.
US-based cancer therapy developer Nkarta Therapeutics, which counts pharmaceutical firms Amgen, Novo and GlaxoSmithKline (GSK) as investors, has set the terms for an initial public offering that will raise $160m at its upper end.
The company intends to issue 10 million shares on the Nasdaq Global Market priced between $14 and $16 each. Cowen and Company, Evercore Group, Stifel Nicolaus and Mizuho Securities USA are the underwriters for the offering.
Nkarta is working on therapies that will involve the…
